Literature DB >> 19911149

Drugs controlling proteinuria of patients with Alport syndrome.

Jian-Guo Li1, Jie Ding, Fang Wang, Hong-Wen Zhang.   

Abstract

BACKGROUND: Proteinuria is one of the risk factors for the progression of renal diseases including Alport syndrome (AS), a hereditary glomerular renal disease. This study aimed to evaluate the efficacy of angiotensin converting enzyme inhibitors (ACEIs) and/or tripterygium, a Chinese herbal medicine widely used in Chinese patients with hematuria and proteinuria, on proteinuria in patients with AS.
METHODS: Twenty-nine children were enrolled into this retrospective study. Patients were divided into 3 therapy groups: ACEI group, tripterygium group, and ACEI plus tripterygium group.
RESULTS: In the 29 children, 23 were male and 6 female. In the ACEI group and the tripterygium group, the effective rate was 87.5% and 25.0%, respectively and in the ACEI plus tripterygium group was 42.9%.
CONCLUSIONS: ACEI is effective in controlling proteinuria of AS patients. Tripterygium should be carefully administered in controlling proteinuria of AS patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19911149     DOI: 10.1007/s12519-009-0059-5

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  17 in total

1.  In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression.

Authors:  E P Cohen; J Lemann
Journal:  Am J Kidney Dis       Date:  1996-02       Impact factor: 8.860

Review 2.  The role of proteinuria in the progression of chronic renal failure.

Authors:  C Burton; K P Harris
Journal:  Am J Kidney Dis       Date:  1996-06       Impact factor: 8.860

3.  [Effects of multi-glycoside of Tripterygium wilfordii Hook. f. on proteinuria and expression of slit diaphragm-associated molecules in rats with anti-thy1.1 glomerulonephritis].

Authors:  Yi-Gang Wan; Wei Sun; Yang Wang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2006-12

4.  Enalapril: antiproteinuric effect in children with nephrotic syndrome.

Authors:  G Lama; I Luongo; A Piscitelli; M E Salsano
Journal:  Clin Nephrol       Date:  2000-06       Impact factor: 0.975

5.  Cyclosporin therapy in patients with Alport syndrome.

Authors:  Marina Charbit; Marie-Claire Gubler; Michèle Dechaux; Marie-France Gagnadoux; Jean-Pierre Grünfeld; Patrick Niaudet
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

6.  Inhibitory effect of Tripterygium wilfordii multiglycoside on increased glomerular albumin permeability in vitro.

Authors:  M Sharma; J Z Li; R Sharma; M Artero; X Ge; E T McCarthy; H Y Wang; V Savin
Journal:  Nephrol Dial Transplant       Date:  1997-10       Impact factor: 5.992

7.  X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.

Authors:  Jean Philippe Jais; Bertrand Knebelmann; Iannis Giatras; Mario DE Marchi; Gianfranco Rizzoni; Alessandra Renieri; Manfred Weber; Oliver Gross; Kai-Olaf Netzer; Frances Flinter; Yves Pirson; Christine Verellen; Jörgen Wieslander; Ulf Persson; Karl Tryggvason; Paula Martin; Jens Michael Hertz; Cornelis Schröder; Marek Sanak; Sarka Krejcova; Maria Fernanda Carvalho; Juan Saus; Corinne Antignac; Hubert Smeets; Marie Claire Gubler
Journal:  J Am Soc Nephrol       Date:  2000-04       Impact factor: 10.121

8.  Enalapril in paediatric patients with Alport syndrome: 2 years' experience.

Authors:  W Proesmans; H Knockaert; D Trouet
Journal:  Eur J Pediatr       Date:  2000-06       Impact factor: 3.183

9.  Long-term effects of cyclosporine A in Alport's syndrome.

Authors:  L Callís; A Vila; M Carrera; J Nieto
Journal:  Kidney Int       Date:  1999-03       Impact factor: 10.612

10.  Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro.

Authors:  Chun-Xia Zheng; Zhao-Hong Chen; Cai-Hong Zeng; Wei-Song Qin; Lei-Shi Li; Zhi-Hong Liu
Journal:  Kidney Int       Date:  2008-05-28       Impact factor: 10.612

View more
  5 in total

Review 1.  Glomerular pathology in Alport syndrome: a molecular perspective.

Authors:  Dominic Cosgrove
Journal:  Pediatr Nephrol       Date:  2011-04-01       Impact factor: 3.714

2.  Ventricular septal defect in a child with Alport syndrome: a case report.

Authors:  Pier Paolo Bassareo; Andrea Raffaele Marras; Giuseppe Mercuro
Journal:  BMC Cardiovasc Disord       Date:  2010-10-05       Impact factor: 2.298

3.  Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.

Authors:  Yanqin Zhang; Fang Wang; Jie Ding; Hongwen Zhang; Xiaoyu Liu; Suxia Wang; Huijie Xiao; Yong Yao; Jingcheng Liu; Xuhui Zhong; Na Guan; Baige Su; Guohong Wu; Lixia Yu
Journal:  Pediatr Nephrol       Date:  2015-08-07       Impact factor: 3.714

4.  HDAC inhibitors in experimental liver and kidney fibrosis.

Authors:  Katrien Van Beneden; Inge Mannaerts; Marina Pauwels; Christiane Van den Branden; Leo A van Grunsven
Journal:  Fibrogenesis Tissue Repair       Date:  2013-01-02

5.  Adverse Events Associated With Treatment of Tripterygium wilfordii Hook F: A Quantitative Evidence Synthesis.

Authors:  Yi Ru; Ying Luo; Yaqiong Zhou; Le Kuai; Xiaoying Sun; Meng Xing; Liu Liu; Yi Lu; Seokgyeong Hong; Xi Chen; Jiankun Song; Yue Luo; Xiaoya Fei; Bin Li; Xin Li
Journal:  Front Pharmacol       Date:  2019-11-06       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.